The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Open accessAbstract
Cardiovascular diseases (CVDs) are the main cause of death among patients with type 2 diabetes mellitus (T2DM), particularly in low- and middle-income countries. To effectively prevent the development of CVDs in T2DM, considerable effort has been made to explore novel preventive approaches, individualized glycemic control and cardiovascular risk management (strict blood pressure and lipid control), together with recently developed glucose-lowering agents and lipid-lowering drugs. This review mainly addresses the important issues affecting the choice of antidiabetic agents and lipid, blood pressure and antiplatelet treatments considering the cardiovascular status of the patient. Finally, we also discuss the changes in therapy principles underlying CVDs in T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cardiovascular disease (CVD) remains a significant threat to people with obesity and type 2 diabetes (T2D), with a two to three times higher incidence compared to people without diabetes or obesity [1, 2].”
From Treatment with orforglipron, an oral glucagon-like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes (2025) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2014) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,609
Self-citationStratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503
Research works printed but not linked: 2
- Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. · DOI · Paper page
- Disease C, Management R. Standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S103-s123.
Cited by
Sorted by citations
Items 401–472 of 472
Salman, M. N., Al-Kashwan, T. A. J., & Aljanabi, A. A. (2025) · Medical Journal of Babylon · doi:10.4103/mjbl.mjbl_1570_23
Souza, L. M., Costa, N. P., & Kashiwabara, T. G. B. (2026) · doi:10.29327/5778434.1-32
Казарян, С. У., Bazarbekovna, B. R., Kassimbekovna, D. A., Р.А., К., Nurlykaimova, Z., Абсатарова, К. С., & Yakubova, M. M. (2026) · Ġylym men densaulyķ saķtau. · doi:10.34689/sh.2025.27.6.019
Yuliet, Y., Hardani, R., Khaerati, K., & Sharon, N. (2026) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2026.00049
Ward, J. K., Shah, M. U., Lee, K., Squires, P. E., & Hills, C. E. (2026) · Diabetic Medicine · doi:10.1111/dme.70247
Wang, B., Tse, E. T. Y., Chui, C. S. L., Lam, C. L. K., & Wan, E. Y. F. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113156
Bladder cancer-induced CVD mortality: Role of CAPG protein
Shen, J. L., Zhao, Z., Li, Z., & Wang, R. (2026) · PLoS ONE · doi:10.1371/journal.pone.0338101
Kuranov, S. O., Larin, M. V., Дмитриевна, Л. И., Meshkova, Y. V., Marenina, M. K., Luzina, O. A., Khvostov, M. V., Tolstikova, T. G., & Salakhutdibov, N. F. (2026) · Medicinal Chemistry Research · doi:10.1007/s00044-026-03532-7
Fokuoh, F. N., Yakubu, A.-S., Agyekum, F., Folson, A. A., Okine, R. N. A., Asamoah, E. A., Kpodonu, J., Amable, E., & Doku, A. (2026) · Cureus · doi:10.7759/cureus.104317
Nguyen, C. M., Zurashvili, S., Ghanem, A. S., Ambrocio, R. P. P. M., Móré, M., & Nagy, A. C. (2026) · BMC Public Health · doi:10.1186/s12889-025-25689-3
“…to individuals aged 15–34), 35–64, and 65 years and above; and educational attainment according to the Hun-garian national education system—Primary (completed 8 years of basic education), Secondary (completed high school with a diploma), and Tertiary (college or university degree or higher) [31].”
Gan, H., Gao, K., Li, Z., Zhang, Y., Li, L., Li, Y., & Guo, H. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1772328
Self-citationPsychosocial and mental health challenges in aging diabetic populations
Aslan, H. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44665-8.00001-8
Frailty, sarcopenia, and diabetes: Managing physical decline
Hajam, Y. A., Bhatti, N., Kaur, A., Ahmed, S., & Rai, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44665-8.00005-5
Hoog, M. M., Minghetti, A., & Valentine, W. J. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01846-8
“An estimated 44.0% of patients with type 2 diabetes in the US are diagnosed with cardiovascular disease (CVD), which is the major cause of early mortality in this population, resulting in the death of at least 50% of patients [5, 6].”
InfluentialPrasad, G. L. V., Rani, R. S., Reddy, B. P., Murala, P., & Arumugam, P. (2026) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2026.109962
Swiderski, J., Gadanec, L. K., Hearth, S., Rowlands, B. D., Murphy, A. J., Apostolopoulos, V., & Zulli, A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1756039
“Considering the underlying involvement of inflammation in the pathophysiology of HF, targeting aspects of the immune system has been seen as a viable approach to improving disease severity and patient outcome (Mesquita et al., 2021; Ma et al., 2022; Bashier et al., 2019; Petrie et al., 2018).”
Elhantery, D., Mokbel, S. A., Hussein, A. M., Tayee, E. M., Desouky, S. E., & Taha, A. M. (2026) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-026-01110-6
“Type 2 diabetes is characterized by abnormal lipid metabolism, hyperglycemia, and insulin resistance [2, 3].”
Xu, W., Wang, S., Yao, H., Luo, R., Li, P., & Lan, X. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1772461
“It is worth noting that there is an extremely close and complex bidirectional relationship between T2DM and cardiovascular diseases (7).”
Eglenoglu, G., Üğe, M., Culcuoglu, I., Esen, Ş., Üzüm, Y., Pamuk, B. Ö., & Yılmaz, H. E. (2026) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2790-9134
“Among its major complications are coronary artery disease and other atherosclerotic vascular disorders [2].”
Research Progress on the Effect of T2DM On Cardiovascular Diseases
苏, 克. (2026) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2026.52107
Li, L., Cui, S., Chow, J., Wu, Y., Yu, Q., Zhong, Y., Wang, Z., Liu, H., Ali, S. S. A., Hu, X., et al. (2026) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.70128
Luzha, A., Henein, M. Y., Bytyci, G., Tafarshiku, R., Bajraktari, G., & Berisha‐Muharremi, V. (2026) · Diabetology · doi:10.3390/diabetology7040072
“…association with ASCVD, several epidemiological and genetic studies have reported a paradoxical association whereby very low Lp(a) concentrations are linked to a higher risk of incident type 2 diabetes, which complicates clinical interpretation of Lp(a) in diabetic populations [12,13].”
Dankoob, V., Shahinfar, H., Ostevari, A., Norouziasl, R., Mohieddin, N., Esmaeili, F., Rafiei, F., & Shab‐Bidar, S. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113260
Kupnovytska, I. H., Romanyshyn, N. M., Klymenko, V. I., Fitkovska, I. P., Gubina, N. V., Kalugina, S. M., & Krasnopolskyi, S. Z. (2026) · The Journal of V N Karazin Kharkiv National University series Medicine · doi:10.26565/2313-6693-2026-58-08
JENDLE, J. H., Adolfsson, P., Hellman, J., Klanger, B., & Ekberg, N. R. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261442987
“60,61 Data on the impact of CGM on CVD and all-cause mortality outcomes are limited.”
Xu, F., Yi, Y., Chi, L., Liu, B., Zhang, W., Wu, Q., & Li, Z. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178847
Cui, X., Li, C., Qin, Y.-H., Liu, J.-J., Jia, C.-K., Sun, X.-Y., Lu, S.-Q., Zhu, Z., & Cao, Z. (2026) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2026.04.153
Goyal, K., Sharma, D., Bansal, P., Mohanty, S., Gandhi, M., Sharma, N., Kanodia, D. S., & Sahai, S. (2026) · Cureus · doi:10.7759/cureus.108205
Menopause Transition: Accelerating Cardiometabolic Risk
Qi, M., & Khoudary, S. R. E. (2026) · Springer eBooks · doi:10.1007/978-3-032-18203-6_7
Najim, R. H., & Taha, M. A. (2026) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v10i2.2913
“Cardiovascular disease is a leading cause of adverse outcomes in patients with T2DM, and this high-risk profile frequently necessitates diagnostic evaluation for coronary artery disease, including coronary angiographic assessment in selected patients [1,2].”
Visceral fat area and remnant cholesterol in type 2 diabetes: Nonlinear associations and thresholds
Chai, D., Zhu, C.-Y., Zhang, Y.-M., & Rao, Z.-C. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i5.117583
Joshi, G., Goutam, N., Shivani, S., Kaushal, K. P., Sharma, A., Harmanbir, K., & Joshi, N. (2026) · Scripta Medica · doi:10.5937/scriptamed57-60346
Davari, A., Ghayourvahdat, A., Mohagheghi, S. Z., Mohammadi, A. T., Azimizonouzi, H., Souri, Z., Jalali-Zefrei, F., Tabaghi, S., & Farzipour, S. (2026) · Current Radiopharmaceuticals · doi:10.1016/j.craph.2026.100053
Zamani, M., Koohpeyma, F., Raeisi, A., Mokarram, P., & Dastghaib, S. (2025) · Iranian Biomedical Journal · doi:10.66224/ibj.5152
Moisi, M. I., Pantiș, C., Dascal, D. G., Vesa, C. M., Ghitea, T. C., Pop, N. O., & Brata, R. D. (2026) · Diabetology · doi:10.3390/diabetology7060105
Atamni, H. J. A., & Rashid, G. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1015708
Wang, X.-L., Wu, W., Nie, S., Nie, C., Su, Y., Cui, R.-Y., Li, X., Peng, G.-C., Yu, R., Wang, J.-R., et al. (2026) · European Journal of Medical Research · doi:10.1186/s40001-026-04630-3
“A multicenter clinical study demonstrated that achieving target levels of blood pressure and lipids significantly reduces the risk of readmission for cardiovascular and cerebrovascular diseases by improving vascular function, stabilizing plaques, and reducing thrombosis [54, 55].”
Zhang, M., Huo, H., Yang, R., Gao, Y., Jia, Y., & Li, J. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1866635
“Antiplatelet therapy requires individualized balancing of ischemic and bleeding risks; aspirin remains a first-line choice but is not recommended for routine use in diabetic patients without established cardiovascular disease (43).”
Vajjiravelu, R., Kirtheka, P. S., Palani, B., Jayakodi, S., & Kirubakaran, D. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100719
Alfadda, A. A., Alqutub, A. N., Sherbeeni, S. M., Aldosary, A. S., Gul, R., Isnani, A. C., Khaleel, M. S., Nawaz, S., Albrahim, H. M., Alqasim, S. M., et al. (2026) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2026.100311
Sun, X., Xu, Y., Wang, J., Zhang, Z., Hou, C., & Li, Q. (2026) · Research Square · doi:10.21203/rs.3.rs-9293169/v1
Shiyi, G., Wang, Y., Wang, J., Zeng, Q., Cheng, Z., Han, Z., Wang, H., Li, M., & Hu, S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1756159
Kim, E., Choi, S., Yoo, H. H., Tahmasebi, S., Bian, Y., & Bae, O.-N. (2026) · Thrombosis and Haemostasis · doi:10.1055/a-2892-7393
Fatima, F., Fawwad, A., Basit, A., Abbas, E., & Aftab, R. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02383-y
“…are known to develop cardiovascular disease at younger ages and lower BMI thresholds and exhibit disproportionate visceral adiposity, early-onset insulin resistance and a pro-inflammatory phenotype even in the absence of overt obesity [3, 8, 19, 27], features prominently reflected in our cohort.”
Izere, C., Yadufashije, C., Bukachi, F., Kamau, A. W., Munene, B., Chitrasree, V., & Agarwal, L. (2026) · Advances in Molecular Imaging · doi:10.4236/ami.2026.151001
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
Hsu, C., & Tain, Y. (2026) · Antioxidants · doi:10.3390/antiox15060769
“Simultaneously, glucose-mediated endothelial injury compromises the cerebral microvasculature, promoting microvascular dysfunction and increasing susceptibility to ischemic stroke [78].”
Alanazi, R. A., Alenezi, A. S., Aldhafeeri, R. J., Alanazi, R. A. M., Alshammari, A. H., Alanazi, G. B., Alenzi, M. K., Alenezi, A. A. A., Alsel, B. T. A., Mersal, F. A., et al. (2026) · Diseases · doi:10.3390/diseases14070233
“In individuals with T2DM, peripheral arterial disease and heart failure often represent early clinical manifestations of CVD [8].”
Deshmukh, H., Shaikh, M., Wilmot, E. G., Kilpatrick, E., Chattopadhyay, S., Sathyapalan, T., & John, J. (2026) · Diabetic Medicine · doi:10.1111/dme.70401
Thanopoulou, A. C., Tentolouris, A., Vlachopoulos, C. V., Gastouniotis, I., Dima, I., Kirlaki, E., Anyfantakis, A., Foukarakis, E. G., Rogdakis, E., Stavrakis, S., et al. (2026) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2026.07.004
de Oliveira, F. M., Neto, F. S. L., Fernandes, E. V., Bocchi, M., de Oliveira, D. M., & Siqueira, C. S. (2026) · International Journal of Translational Medicine · doi:10.3390/ijtm6030029
“Consequently, there is growing interest in identifying molecular biomarkers capable of complementing conventional clinical risk assessment tools and providing insights into the biological mechanisms underlying cardiovascular risk progression [1,10].”
Azzam, A. Y., Essibayi, M. A., Rai, P., Salim, H. A., Alhasan, M. S., Anindo, M., Hashem, A. M., Dmytriw, A. A., Altschul, D., Yedavalli, V. S., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.102917 · Cited by 1
Liu, X., Bi, L., Jin, Q., Hu, H., Liu, W., & Cheng, L. (2026) · The Journal of Cardiovascular Nursing · doi:10.1097/jcn.0000000000001323
Zeng, C., Liu, M., Tang, P., Xin, Y., & Hu, X. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1787383
Deng, J., Liao, B., Huang, H., Yu, Y., Wang, Q., Tian, J., & Tang, H. (2026) · The International Journal of Cardiovascular Imaging · doi:10.1007/s10554-026-03789-4
Kim, E. A., Lee, M., & Nam, S. (2026) · Sleep Medicine · doi:10.1016/j.sleep.2026.109186
Type 2 Diabetes Mellitus and Chronic Venous Disease of the Lower Extremities: A Narrative Review
Saucedo, J. R., Villordo, D. G., Laparra-Escareño, H., García, N. A. R., Cervera, L. F. F., Sinay, I. R., Guzmán, J. R., & Zingg, D. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01891-3
“The high concomitant incidence of both diabetes and CVD and the commonalities in the pathophysiology of both diseases raise the question about the possible synergy between both processes, which may even share a causal link [10].”
Ahmed, S., McCollin, S. P., Martí-Carvajal, A. J., Akus, M., Baron, D. W., Razzaq, S. A., Scudder, P. N., Honigsberg, E. J., Nasir, S., Peng, K., et al. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016380
Patil, S. G., Patil, L. R., Shetty, V. V., Guru Praveen, S., Dharani, E., Rajanna, M., Vadiraj, H. S., Kumbar, L., Aithal, K. R., Gadad, B., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-119948
Prediabetes: Impact on cardiovascular risk and emerging therapeutic strategies
Biondi, F., Ghelardoni, S., Monti, E., Арманович, А. А., Caterina, R. D., & Madonna, R. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.121898
Evaluation of Dibeston’s Impact on Kidney Excretory Function in Diabetic Conditions
Rahman, A., Islam, F., & Ahmed, T. (2022) · Journal of Applied Pharmaceutical Technologies and Systems · doi:10.68159/l473833226
Cross-Platform Analysis of Endothelial Transcriptomic Changes Associated with DiabetesPreprint
Luo, Y., Huang, K., Sun, J., Qi, M., Tang, X., & Chen, Z. (2026) · Research Square · doi:10.21203/rs.3.rs-10781628/v1
Evidence-based insights into plant-derived antidiabetic foods and nutraceuticals
Ahda, M., Prastowo, I., & Nurani, L. H. (2026) · Food Research International Translational Research · doi:10.1016/j.frintr.2026.100012
Quesada, J. A., Pomares, F., Esquerdo-Arroyo, A., Carratalá‐Munuera, C., Gil-Guillén, V. F., Orozco‐Beltrán, D., & López‐Pineda, A. (2026) · Postgraduate Medical Journal · doi:10.1093/postmj/qgag124
Sultan, S. R., Hajji, F. A., & Fatani, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15197580
“Type 2 diabetes mellitus (T2DM) is a well-established independent risk factor for cardiovascular disease, increasing the risk of coronary arterial disease, stroke, and peripheral arterial disease (PAD) [5].”
Li, B., Zheng, Z., He, J., Song, Y., Bian, X., Song, C., Fu, R., & Dou, K. (2026) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.70925
Igna, A. D., Petca, B.-L., Popovici, P.-A., Moga, I., Moga, T. D., Ghitea, T. C., Cinezan, C., & Popoviciu, M. S. (2026) · Diagnostics · doi:10.3390/diagnostics16193201
“Reframing the primary endpoint as six-month glycemic status and restricting a sensitivity analysis to baseline HbA1c ≥ 7.0% avoids overstating the model as a predictor of treatment response [9–14].”
InfluentialNama, P., Roy, D., Bhunia, P. K., Biswas, K., Suladze, S., Reif, B., Biswas, R., Mroue, K., Ghosh, D., Harikishore, A., et al. (2026) · Biophysical Chemistry · doi:10.1016/j.bpc.2026.107720
Meta-Inflammation in Type 2 Diabetes Mellitus: Theoretical, Methodological, and Clinical Aspects
Zhuravleva, Y. A., & Gusev, E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198891
“…and lipotoxicity effects, which can cause damage to various organs and subsequently lead to vascular and other complications: retinopathy, nephropathy, neuropathy, hypertension, ischemic heart disease, thrombophilia, accelerated development of atherosclerosis, and chronic heart failure [6,7].”
Sun, Y., Feng, B., Zhang, Y., Ou, D., Pan, D., Wang, S., Shen, F., Li, X., & Xu, D. M. (2026) · Academic Radiology · doi:10.1016/j.acra.2026.09.036
Wang, X., Wang, S., Xiao, X., Jin, Z., Jiang, Z., Wu, B., Deng, P., & Xiao, W. (2026) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2026.107135
Zhang, L., Meng, L., Zhang, Y., Zhao, L., Liu, Y., Wang, R., Zhou, J., & Li, K. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1995413
“Chronic hyperglycemia and insulin resistance contribute to endothelial dysfunction, oxidative stress, and vascular injury, thereby accelerating cardiovascular complications in diabetes (9, 10).”
Metadata
- Authors
- Ma, C.-X., Ma, X.-N., Guan, C.-H., Li, Y.-D., Mauricio, D., & Fu, S.-B.
- Venue
- Cardiovascular Diabetology
- Published
- 2022-05-14
- Volume
- 21
- Issue
- 1
- Pages
- 74-74
- ISSN
- 1475-2840 (ISSN-L)
- PMC
- PMC9107726
- OpenAlex
- W4280586315
- Cited by
- 464
- References
- 137
- Citations by year
- 2026: 97 · 2025: 153 · 2024: 137 · 2023: 69 · 2022: 8
- FWCI
- 13.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Cardiovascular Diabetology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
- Lanzhou University Institutional Repository (submittedVersion, cc-by-nc-sa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- the Lanzhou Chengguan District Science and Technology Plan Project (2021-9-19)
- the hospital fund of the First Hospital of Lanzhou University (ldyyyn2020-93)
- the Construction Program of Gansu Provincial Clinical Medical Research Center for Endocrine Diseases (20JR10FA667)
- the Special Funds of Science and Technology Development of the Chinese Central Government to guide Local (1004TCYA032)
- the Gansu Provincial Natural Science Foundation (20JR10RA681)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, cardiovascular disease, personalized medicine, cardiovascular risk management, glycemic control, blood pressure control, lipid-lowering therapy, glucose-lowering agents, antiplatelet therapy, cardiovascular disease prevention, low- and middle-income countries
- MeSH terms
- Blood Glucose, Blood Pressure, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Lipids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
